SUO 2018: PSMA-Guided Salvage Lymph Node Dissection
Phoenix, Arizona (UroToday.com) Derya Tilki presented novel PSMA-guided salvage lymph node dissection (sLND) methodology. First, she started by reviewing the impact of biochemical recurrence (BCR) in prostate cancer outcomes.
SUO 2018: PROTUX Clinical Trial: Rituximab Neoadjuvant Therapy in High Risk Prostate Cancer Patients Scheduled to Undergo Radical Prostatectomy
Phoenix, Arizona (UroToday.com) To date, we have had little success with neoadjuvant therapies for high-risk localized prostate cancer (PCa) prior to definitive therapy with radical prostatectomy (RP). There are ongoing trials looking at the combination of chemotherapy, ADT and androgen-axis targeted therapies (ARATs), but these have yet to report.
SUO 2018: Gene Expression Classifier Utility in Men at High Risk of Recurrence Following Radical Prostatectomy (G-MINOR)
Phoenix, Arizona (UroToday.com) The Decipher assay is a molecular genomic biomarker based on tissue pathology that serves a genomic classifier (GC) for prostate cancer (PCa). It has previously been validated in the post-radical prostatectomy (RP) setting as a predictor of metastasis1 and therefore as a potential biomarker to determine the need for adjuvant radiotherapy in high-risk patients.2 However, all this work has been based on retrospective data and the authors of this study report on the first prospective randomized trial of the Decipher GC in this study population.
SUO 2018: Pathologic Progression is the Dominant Driver of Conversion to Radical Therapy Post Vascular
Phoenix, Arizona (UroToday.com) Partial gland ablation or focal therapy is an increasingly attractive option for men with high volume Gleason 6 disease or low-volume Gleason 7 disease that are on the borderline for active surveillance. While early results for focal therapy studies have been promising, with moderate oncologic benefit, feasible salvage in the setting of progression and preservation of sexual and urinary function, long-term oncologic data is lacking.
SUO 2018: Lithium Treatment Alters Histone Lysine Modification in Prostate Cancers
Phoenix, Arizona (UroToday.com) Lithium is an established treatment for psychiatric conditions, though with known significant side effects. However, in this phase 1 study, the authors assess lithium in men with localized prostate cancer (PCa). Current treatment paradigms for men with localized PCa are surgery or radiation, with no established systemic therapies.
SUO 2018: Treatment of the Primary Is Not Necessary, or Is It?
Phoenix, Arizona (UroToday.com) In this debate during the prostate cancer session, the two speakers look at the question of primary therapy for metastatic prostate cancer. Both ultimately agreed on the final message.
SUO 2018: Long-term Outcomes of Active Surveillance for Prostate Cancer – The Memorial Sloan Kettering Cancer Center Experience
Phoenix, Arizona (UroToday.com) Dr. Carlsson presented the Memorial Sloan Kettering Cancer Center experience with active surveillance over a long-term follow-up. Most patients with low-risk prostate cancer end up getting treatment, however, the rate of active surveillance in the US over the last years has increased significantly to almost 50% of low-risk patients. Interestingly, the rate of active surveillance in Sweden is extremely high for low-risk patients (~80%) and for intermediate risk patients as well (~20%).